These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28836054)

  • 1. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
    Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
    Ali MA; Elsalakawy WA
    Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
    Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
    Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
    J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.
    Malhotra H; Sharma P; Malhotra B; Bhargava S; Jasuja S; Kumar M
    Indian J Med Res; 2015 Aug; 142(2):175-82. PubMed ID: 26354214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
    Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
    Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.
    da Cunha Vasconcelos F; Mauricio Scheiner MA; Moellman-Coelho A; Mencalha AL; Renault IZ; Rumjanek VM; Maia RC
    Leuk Res; 2016 Dec; 51():3-10. PubMed ID: 27770655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
    Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
    Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
    Salimizand H; Amini S; Abdi M; Ghaderi B; Azadi NA
    Tumour Biol; 2016 Jan; 37(1):791-8. PubMed ID: 26250462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients.
    Rinaldi I; Nova R; Widyastuti R; Priambodo R; Instiaty I; Louisa M
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3331-3334. PubMed ID: 31759356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.
    Galeotti L; Ceccherini F; Domingo D; Laurino M; Polillo M; Di Paolo A; Baratè C; Fava C; D'Avolio A; Cervetti G; Guerrini F; Fontanelli G; Ciabatti E; Grassi S; Arrigoni E; Danesi R; Petrini M; Cornolti F; Saglio G; Galimberti S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):767-773. PubMed ID: 28289867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib.
    Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
    Med Oncol; 2015 Aug; 32(8):213. PubMed ID: 26143137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
    Singh O; Chan JY; Lin K; Heng CC; Chowbay B
    PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
    Vivona D; Bueno CT; Lima LT; Hirata RD; Hirata MH; Luchessi AD; Zanichelli MA; Chiattone CS; Guerra-Shinohara EM
    Blood Cells Mol Dis; 2012 Feb; 48(2):132-6. PubMed ID: 22134106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
    Dulucq S; Bouchet S; Turcq B; Lippert E; Etienne G; Reiffers J; Molimard M; Krajinovic M; Mahon FX
    Blood; 2008 Sep; 112(5):2024-7. PubMed ID: 18524988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.